Cannabis Seed Compound Trilinolein Alleviates Eczema by Restoring Mitochondrial Function in Skin Cells
Trilinolein, a fat molecule derived from cannabis seeds, improved atopic dermatitis in mice by repairing mitochondrial dysfunction and restoring the skin barrier through the AhR-Nrf2 pathway.
Quick Facts
What This Study Found
Topically applied trilinolein improved DNCB-induced eczema-like lesions in mice, increased terminal differentiation proteins, decreased oxidative stress marker NOX2, restored mitochondrial morphology and membrane potential, and reduced mitochondrial DNA release in inflamed skin cells. These effects depended on the AhR signaling pathway.
Key Numbers
Trilinolein increased expression of terminal differentiation proteins and decreased NOX2 expression, comparable to the positive control crisaborole. It reduced ROS fluorescence intensity, restored mitochondrial membrane potential, and decreased mtDNA release in stimulated keratinocytes. AhR, CYP1A1, and Nrf2 protein expression increased in a dose-dependent manner.
How They Did This
Combined approach using single-cell transcriptome analysis of chronic atopic dermatitis patients vs healthy controls, DNCB-induced eczema model in BALB/c mice, and IL-4/TNF-alpha-stimulated HaCaT keratinocytes. HPLC-ESI-MS/MS identified active compounds from Cannabis fructus. Proteomics explored mechanisms.
Why This Research Matters
Atopic dermatitis affects millions of people and current treatments often have significant side effects. Trilinolein from cannabis seeds targets a newly recognized disease mechanism -- mitochondrial dysfunction in skin cells -- and performed comparably to the prescription drug crisaborole in this preclinical model.
The Bigger Picture
Cannabis seeds (Cannabis fructus) have been used in traditional medicine and cosmetics for centuries. Identifying trilinolein as an active compound with a clear molecular mechanism connects traditional use to modern pharmacology and opens a pathway for developing targeted dermatological treatments from cannabis-derived ingredients.
What This Study Doesn't Tell Us
Preclinical study only. Mouse skin differs significantly from human skin. The DNCB-induced model does not fully replicate the complexity of human atopic dermatitis. Clinical trials in humans are needed to confirm efficacy and safety.
Questions This Raises
- ?Would trilinolein be effective in human atopic dermatitis patients?
- ?How does it compare to existing topical treatments in terms of long-term efficacy and side effects?
Trust & Context
- Key Stat:
- Trilinolein performed comparably to prescription drug crisaborole in mouse eczema model
- Evidence Grade:
- Preliminary: well-designed preclinical study with clear mechanistic evidence across multiple model systems, but not yet tested in humans.
- Study Age:
- 2024 preclinical study.
- Original Title:
- Targeting mitochondrial dysfunction in atopic dermatitis with trilinolein: A triacylglycerol from the medicinal plant Cannabis fructus.
- Published In:
- Phytomedicine : international journal of phytotherapy and phytopharmacology, 132, 155856 (2024)
- Authors:
- Wang, Yi(2), Lu, Hanzhi, Cheng, Linyan, Guo, Wanjun, Hu, Yue, Du, Xinran, Liu, Xin, Xu, Mingyuan, Liu, Yeqiang, Zhang, Yanbin, Xi, Ruofan, Wang, Peiyao, Liu, Xin, Duan, Yanjuan, Zhu, Jianyong, Li, Fulun
- Database ID:
- RTHC-05799
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is trilinolein?
Trilinolein is a triacylglycerol (fat molecule) found in Cannabis fructus -- the mature fruit/seeds of the cannabis plant. It is not a cannabinoid like THC or CBD but a lipid compound with its own biological activity.
How does mitochondrial dysfunction relate to eczema?
Single-cell analysis of atopic dermatitis patients revealed abnormal keratinocyte differentiation and oxidative stress damage. Trilinolein addresses this by restoring mitochondrial membrane potential and reducing oxidative damage, which helps repair the skin barrier.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-05799APA
Wang, Yi; Lu, Hanzhi; Cheng, Linyan; Guo, Wanjun; Hu, Yue; Du, Xinran; Liu, Xin; Xu, Mingyuan; Liu, Yeqiang; Zhang, Yanbin; Xi, Ruofan; Wang, Peiyao; Liu, Xin; Duan, Yanjuan; Zhu, Jianyong; Li, Fulun. (2024). Targeting mitochondrial dysfunction in atopic dermatitis with trilinolein: A triacylglycerol from the medicinal plant Cannabis fructus.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 132, 155856. https://doi.org/10.1016/j.phymed.2024.155856
MLA
Wang, Yi, et al. "Targeting mitochondrial dysfunction in atopic dermatitis with trilinolein: A triacylglycerol from the medicinal plant Cannabis fructus.." Phytomedicine : international journal of phytotherapy and phytopharmacology, 2024. https://doi.org/10.1016/j.phymed.2024.155856
RethinkTHC
RethinkTHC Research Database. "Targeting mitochondrial dysfunction in atopic dermatitis wit..." RTHC-05799. Retrieved from https://rethinkthc.com/research/wang-2024-targeting-mitochondrial-dysfunction-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.